{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:57Z","timestamp":1787021157558,"version":"3.56.0"},"reference-count":16,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncol Adv"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Primary analysis of KEYNOTE-942 (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03897881\">NCT03897881<\/jats:ext-link>\n                      ) demonstrated prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) for the individualized neoantigen therapy intismeran autogene (intismeran; formerly mRNA-4157 or V940) with pembrolizumab versus pembrolizumab alone in high-risk resected melanoma. This update provides an additional year of follow-up to assess longer-term efficacy\/safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>KEYNOTE-942 is a phase IIb study in patients with completely resected high-risk (stage IIIB to IV) cutaneous melanoma who were randomly assigned to receive either intismeran plus pembrolizumab or pembrolizumab alone. The primary end point was RFS; secondary end points included DMFS and safety\/tolerability. Overall survival and biomarker data were exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>With a median follow-up of approximately 3 years, and a minimum of approximately 2 years (median [range] 34.9 [25.1-51.0] months), the combination continued to demonstrate improvement in RFS (hazard ratio [HR], 0.510 [80% CI, 0.351 to 0.743]) and DMFS (HR, 0.384 [80% CI, 0.227 to 0.650]) compared with pembrolizumab. The safety profile was consistent with earlier findings. Most adverse events (AEs) were low-grade, with serious AEs, immune-related AEs, and grade 3\/4 events comparable between the arms and no grade 4\/5 events related to intismeran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Intismeran plus pembrolizumab significantly prolongs RFS and DMFS compared with pembrolizumab alone for the adjuvant treatment of resected high-risk melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/oa-25-00008","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:59:05Z","timestamp":1770929945000},"source":"Crossref","is-referenced-by-count":4,"title":["Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma"],"prefix":"10.1200","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-4104","authenticated-orcid":true,"given":"Matteo S.","family":"Carlino","sequence":"first","affiliation":[{"name":"Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[{"name":"Hollywood Private Hospital &amp; Edith Cowan University, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-6137","authenticated-orcid":true,"given":"Tarek","family":"Meniawy","sequence":"additional","affiliation":[{"name":"Saint John of God Subiaco Hospital, Subiaco, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7178-8777","authenticated-orcid":true,"given":"George","family":"Ansstas","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-9001","authenticated-orcid":true,"given":"Matthew H.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-0530","authenticated-orcid":true,"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center Research Institute, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-7418","authenticated-orcid":true,"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":true,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":true,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1752-7282","authenticated-orcid":true,"given":"Mark","family":"Faries","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-7575","authenticated-orcid":true,"given":"Thuy T.","family":"Tran","sequence":"additional","affiliation":[{"name":"Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lance","family":"Cowey","sequence":"additional","affiliation":[{"name":"Texas Oncology PA, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pecora","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montaser","family":"Shaheen","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-2093","authenticated-orcid":true,"given":"Jennifer","family":"Segar","sequence":"additional","affiliation":[{"name":"University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Medina","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-8498","authenticated-orcid":true,"given":"Geoffrey T.","family":"Gibney","sequence":"additional","affiliation":[{"name":"Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":true,"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0925-3325","authenticated-orcid":true,"given":"Sajeve","family":"Thomas","sequence":"additional","affiliation":[{"name":"Orlando Health, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8953","authenticated-orcid":true,"given":"Elizabeth I.","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-4655","authenticated-orcid":true,"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-2957","authenticated-orcid":true,"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8015","authenticated-orcid":true,"given":"Meghan J.","family":"Mooradian","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Howle","sequence":"additional","affiliation":[{"name":"Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azim","family":"Khan","sequence":"additional","affiliation":[{"name":"Hollywood Private Hospital &amp; Edith Cowan University, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Huang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Healy","sequence":"additional","affiliation":[{"name":"Merck &amp; Co, Inc, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Feldman","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudha","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Rao","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-2795","authenticated-orcid":true,"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-7407","authenticated-orcid":true,"given":"Lakshmi","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzhang","family":"Mao","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Posadas","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Brown","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Zaks","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4794-1477","authenticated-orcid":true,"given":"Robert S.","family":"Meehan","sequence":"additional","affiliation":[{"name":"Moderna, Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-9264","authenticated-orcid":true,"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01206-4"},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri G","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, et al: mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 130:5976-5988, 2020","journal-title":"J Clin Invest"},{"key":"e_1_3_10_5_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume":"37","author":"Burris HA","year":"2019","unstructured":"Burris HA, Patel MR, Cho DC, et al: A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. J Clin Oncol 37, 2019 (suppl 15; abstr 2523)","journal-title":"J Clin Oncol"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0158"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.041"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_10_15_2","volume-title":"College of American Pathologists (CAP) Practical Guide to Specimen Handling in Surgical Pathology","author":"Lott R","year":"2023","unstructured":"Lott R, Tunnicliffe J, Sheppard E, et al: College of American Pathologists (CAP) Practical Guide to Specimen Handling in Surgical Pathology. 2023"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.12.006"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:21:30Z","timestamp":1775143290000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/OA-25-00008"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00008","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e2500008"}}